{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:09:37Z","timestamp":1787688577329,"version":"build-2784847793"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019304","name":"Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019305","name":"Manipal Academy of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019305","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijpx.2025.100417","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:59:22Z","timestamp":1760223562000},"page":"100417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["An overview of advanced nanocarrier systems for Ibrutinib delivery: overcoming pharmacokinetic barriers and enabling targeted cancer therapy"],"prefix":"10.1016","volume":"10","author":[{"given":"Akshay","family":"Shetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesha","family":"Keerikkadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragathi Devanand","family":"Bangera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamshi Krishna","family":"Tippavajhala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahalaxmi","family":"Rathnanand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpx.2025.100417_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2024.103331","article-title":"Biohybrid nano-platforms manifesting effective cancer therapy: Fabrication, characterization, challenges and clinical perspective","volume":"335","author":"Aalhate","year":"2025","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.ijpx.2025.100417_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12935-024-03259-8","article-title":"Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies","volume":"24","author":"Abdolvahab","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ijpx.2025.100417_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202302902","article-title":"Insights into targeted and stimulus-responsive nanocarriers for brain cancer treatment","volume":"13","author":"Abousalman-Rezvani","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ijpx.2025.100417_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.113875","article-title":"Ibrutinib topical delivery for melanoma treatment: the effect of nanostructured lipid carriers\u2019 composition on the controlled drug skin deposition","volume":"237","author":"Albuquerque","year":"2024","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ijpx.2025.100417_bb0025","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.55730\/1300-0527.3466","article-title":"The investigation of parameters affecting Ibrutinib release from chitosan\/ tripolyphosphate\/carbon nanofiber composite microspheres","volume":"46","author":"Armutcu","year":"2022","journal-title":"Turk. J. Chem."},{"key":"10.1016\/j.ijpx.2025.100417_bb0030","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41467-025-56318-7","article-title":"Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL","volume":"16","author":"Arseni","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpx.2025.100417_bb0035","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/polym14183886","article-title":"Preparation and optimization of ibrutinib-loaded nanoliposomes using response surface methodology","volume":"14","author":"Ashar","year":"2022","journal-title":"Polymers"},{"key":"10.1016\/j.ijpx.2025.100417_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0310492","article-title":"Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system","volume":"19","author":"Ashar","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpx.2025.100417_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.procbio.2024.04.002","article-title":"Unlocking the potential of ibrutinib: a comprehensive review on its role in the multifaceted landscape of cancer therapy","volume":"143","author":"Azizuddin","year":"2024","journal-title":"Process Biochem."},{"key":"10.1016\/j.ijpx.2025.100417_bb0050","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s12668-025-01995-3","article-title":"Development, optimization, and characterization of ibrutinib-loaded chitosomes using Box-behnken design: in vitro evaluation and in vivo pharmacokinetic studies","volume":"15","author":"Bangera","year":"2025","journal-title":"BioNanoSci"},{"key":"10.1016\/j.ijpx.2025.100417_bb0055","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1021\/acs.jcim.4c00023","article-title":"Computational investigation of the covalent inhibition mechanism of bruton\u2019s tyrosine kinase by ibrutinib","volume":"64","author":"Barragan","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ijpx.2025.100417_bb0060","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1007\/s12668-024-01445-6","article-title":"Unleashing the potential of Ibrutinib-Loaded Nanoparticles for Cancer Treatment\u2014a Comprehensive Review","volume":"14","author":"Behzadmehr","year":"2024","journal-title":"BioNanoSci"},{"key":"10.1016\/j.ijpx.2025.100417_bb0065","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.3390\/cancers17142303","article-title":"Advances in doxorubicin chemotherapy: emerging polymeric nanocarriers for drug loading and delivery","volume":"17","author":"Bhadran","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ijpx.2025.100417_bb0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000528019","article-title":"Ibrutinib and bruton\u2019s tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias\/sudden cardiac death","volume":"68","author":"Boriani","year":"2023","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijpx.2025.100417_bb0075","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/10717544.2012.724472","article-title":"Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib","volume":"19","author":"Bragagni","year":"2012","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijpx.2025.100417_bb0080","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for waldenstr\u00f6m\u2019s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ijpx.2025.100417_bb0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","article-title":"Ibrutinib: first global approval","volume":"74","author":"Cameron","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ijpx.2025.100417_bb0090","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1080\/14656566.2021.1941864","article-title":"Evaluating ibrutinib for the treatment of relapsed\/refractory marginal zone lymphoma","volume":"22","author":"Cavalloni","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ijpx.2025.100417_bb0095","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.32604\/or.2025.055100","article-title":"Advances and challenges in leukemia treatment: a focus on monoclonal antibodies and emerging therapies","volume":"33","author":"Chagas","year":"2025","journal-title":"OR"},{"key":"10.1016\/j.ijpx.2025.100417_bb0100","series-title":"Small Molecules in Hematology","first-page":"133","article-title":"Ibrutinib","author":"Charalambous","year":"2018"},{"key":"10.1016\/j.ijpx.2025.100417_bb0105","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.3390\/genes14122182","article-title":"Resisting the resistance: navigating BTK mutations in Chronic Lymphocytic Leukemia (CLL)","volume":"14","author":"Chirino","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.ijpx.2025.100417_bb0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/17474086.2022.2067526","article-title":"Cardiotoxicity of BTK inhibitors: ibrutinib and beyond","volume":"15","author":"Christensen","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0115","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s10311-018-0763-2","article-title":"Cyclodextrins, from molecules to applications","volume":"16","author":"Crini","year":"2018","journal-title":"Environ. Chem. Lett."},{"key":"10.1016\/j.ijpx.2025.100417_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202410030","article-title":"Stimuli-responsive nano drug delivery systems for the treatment of neurological diseases","volume":"21","author":"Dai","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.ijpx.2025.100417_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2022.100073","article-title":"Complex dispersions of poloxamers and mesoporous carriers with ibrutinib","volume":"8","author":"Dain","year":"2022","journal-title":"OpenNano"},{"key":"10.1016\/j.ijpx.2025.100417_bb0130","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12967-021-03136-2","article-title":"Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence","volume":"19","author":"Davis","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ijpx.2025.100417_bb0135","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1080\/10428194.2018.1460474","article-title":"A drug\u2013drug interaction study of ibrutinib with moderate\/strong CYP3A inhibitors in patients with B-cell malignancies","volume":"59","author":"de Jong","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ijpx.2025.100417_bb0140","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s13318-021-00746-5","article-title":"Assessment of pharmacokinetic parameters of daidzein-containing nanosuspension and nanoemulsion formulations after oral administration to Rats","volume":"47","author":"Demirt\u00fcrk","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ijpx.2025.100417_bb0145","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/0008-5472.CAN-21-0218","article-title":"Targeting cellular iron homeostasis with ironomycin in diffuse large B-cell lymphoma","volume":"82","author":"Devin","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpx.2025.100417_bb0150","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9954443","article-title":"Toxicity of nanoparticles in biomedical application: nanotoxicology","volume":"2021","author":"Egbuna","year":"2021","journal-title":"J. Toxicol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0155","series-title":"Development and Characterization of a Novel Model of Ibrutinib Resistance in Chronic Lymphocytic Leukemia (CLL) that Displays Sensitivity to PI3K Inhibition","author":"Ehiremen","year":"2021"},{"key":"10.1016\/j.ijpx.2025.100417_bb0160","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1208\/s12249-024-02957-w","article-title":"Rosuvastatin flexible chitosomes: development, in vitro evaluation and enhancement of anticancer efficacy against HepG2 and MCF7 cell lines","volume":"25","author":"Eleraky","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2025.100417_bb0165","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ijpx.2025.100417_bb0170","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejpb.2023.07.008","article-title":"Quality by design endorsed fabrication of Ibrutinib-loaded human serum albumin nanoparticles for the management of leukemia","volume":"190","author":"Famta","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2025.100417_bb0175","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-020-04137-6","article-title":"Drug interactions with Bruton\u2019s tyrosine kinase inhibitors: clinical implications and management","volume":"86","author":"Fancher","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202109769","article-title":"Tumor-cell-specific targeting of ibrutinib: introducing electrostatic antibody-inhibitor conjugates (AiCs)","volume":"61","author":"Faust","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ijpx.2025.100417_bb0185","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/hon.3032","article-title":"Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia","volume":"40","author":"Forestieri","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0190","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3390\/pharmaceutics15041186","article-title":"Folic acid-modified ibrutinib-loaded silk fibroin nanoparticles for cancer cell therapy with over-expressed folate receptor","volume":"15","author":"Fuster","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2025.100417_bb0195","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for cancer therapy: current progress and challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.ijpx.2025.100417_bb0200","series-title":"Nanotechnology theranostics in livestock diseases and management","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/978-981-16-1610-5_31","article-title":"Regulatory Issues in Nanotechnology","author":"Ghosh","year":"2024"},{"key":"10.1016\/j.ijpx.2025.100417_bb0205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12951-025-03252-x","article-title":"Metal\u2013organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives","volume":"23","author":"Guo","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/kinasesphosphatases3020009","article-title":"Nanotechnology-based delivery systems for enhanced targeting of tyrosine kinase inhibitors: exploring inorganic and organic nanoparticles as targeted carriers","volume":"3","author":"Gvozdeva","year":"2025","journal-title":"Kinases Phosphatases"},{"key":"10.1016\/j.ijpx.2025.100417_bb0215","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00277-023-05342-y","article-title":"Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia","volume":"102","author":"Hegde","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0220","doi-asserted-by":"crossref","first-page":"8611","DOI":"10.2147\/IJN.S534137","article-title":"A Review on QbD-Driven Optimization of Lipid Nanoparticles for Oral Drug delivery: from Framework to Formulation","volume":"20","author":"Hidayat","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2025.100417_bb0225","doi-asserted-by":"crossref","first-page":"21365","DOI":"10.1039\/D3RA02969G","article-title":"Nanoparticle-based drug delivery systems targeting cancer cell surfaces","volume":"13","author":"Hong","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.ijpx.2025.100417_bb0230","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3390\/biomedicines11072080","article-title":"Evaluation of folate-functionalized nanoparticle drug delivery systems\u2014Effectiveness and concerns","volume":"11","author":"Ibrahim","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijpx.2025.100417_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2025.126882","article-title":"Utilizing \u03b2CD host-guest complexation to substantially enhance the aqueous solubility of anticancer drug ibrutinib","volume":"421","author":"Ismail","year":"2025","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ijpx.2025.100417_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103103","article-title":"Liposome mediated topical delivery of Ibrutinib and Curcumin as a synergistic approach to combat imiquimod induced psoriasis","volume":"68","author":"Jain","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0245","series-title":"A Phase 1 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Subjects With Recurrent Mature B-Cell Neoplasms","author":"Janssen Pharmaceutical","year":"2018"},{"key":"10.1016\/j.ijpx.2025.100417_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2025.106963","article-title":"Enhanced bioavailability and therapeutic efficacy of Ibrutinib and naringenin-loaded self-nanoemulsifying drug delivery system","volume":"109","author":"Jati","year":"2025","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2022.121834","article-title":"Comprehending binding features between ibrutinib and Human Alpha-1 acid glycoprotein: combined experimental approaches and theoretical simulations","volume":"285","author":"Jiang","year":"2023","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.ijpx.2025.100417_bb0260","article-title":"Integrative green synthesis and molecular simulation of ibrutinib cocrystals for enhanced biopharmaceutical performance and in vivo pharmacokinetics","volume":"10","author":"Kara","year":"2025","journal-title":"Int. J. Pharm.: X"},{"key":"10.1016\/j.ijpx.2025.100417_bb0265","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40360-024-00832-9","article-title":"Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies","volume":"26","author":"Karimi","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0270","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1208\/s12249-025-03130-7","article-title":"Dasatinib pharmacokinetics and advanced nanocarrier strategies: from systemic limitations to targeted success","volume":"26","author":"Keerikkadu","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2025.100417_bb0275","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/pharmaceutics17060783","article-title":"Innovative approaches in cancer treatment: emphasizing the role of nanomaterials in tyrosine kinase inhibition","volume":"17","author":"Kurillov\u00e1","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2025.100417_bb0280","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/acs.molpharmaceut.2c00709","article-title":"Targeting Ibrutinib to tumor-infiltrating T cells with a sialic acid conjugate-modified phospholipid complex for improved tumor immunotherapy","volume":"20","author":"Li","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2025.100417_bb0285","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3390\/pharmaceutics14091876","article-title":"Ibrutinib Inhibits angiogenesis and tumorigenesis in a BTK-independent manner","volume":"14","author":"Liu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2025.100417_bb0290","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400652","article-title":"Cuproptosis: advances in stimulus-responsive nanomaterials for cancer therapy","volume":"13","author":"Lu","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ijpx.2025.100417_bb0295","doi-asserted-by":"crossref","DOI":"10.1515\/ntrev-2023-0218","article-title":"Micelle-based nanoparticles with stimuli-responsive properties for drug delivery","volume":"13","author":"Maboudi","year":"2024","journal-title":"Nanotechnol. Rev."},{"key":"10.1016\/j.ijpx.2025.100417_bb0300","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1039\/D5TB00419E","article-title":"Benchmarking of pH-responsive mixed micelles for repurposed breast cancer therapy of ibrutinib with molecular modeling and pharmacokinetic insights","volume":"13","author":"Maji","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ijpx.2025.100417_bb0305","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11523-025-01133-9","article-title":"Leveraging the immunomodulatory potential of ibrutinib for improved outcomes of T cell-mediated therapies of B cell malignancies: a narrative review","volume":"20","author":"Miklos","year":"2025","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0310","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/14737140.2024.2379921","article-title":"The new life of ibrutinib therapy in CLL: enhancing personalized approaches","volume":"24","author":"Molica","year":"2024","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.ijpx.2025.100417_bb0315","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1080\/1061186X.2025.2468749","article-title":"Local delivery of ibrutinib by folate receptor-mediated targeting PLGA\u2013PEG nanoparticles to glioblastoma multiform: in vitro and in vivo studies","volume":"33","author":"Morshedi","year":"2025","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijpx.2025.100417_bb0320","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3390\/polym16141961","article-title":"Stability studies of amorphous ibrutinib prepared using the quench-cooling method and its dispersions with soluplus\u00ae","volume":"16","author":"Mucha","year":"2024","journal-title":"Polymers"},{"key":"10.1016\/j.ijpx.2025.100417_bb0325","doi-asserted-by":"crossref","first-page":"18684","DOI":"10.1007\/s10853-021-06559-w","article-title":"Ibrutinib conjugated surface-functionalized multiwalled carbon nanotubes and its biopolymer composites for targeting prostate carcinoma","volume":"56","author":"Murugesan","year":"2021","journal-title":"J. Mater. Sci."},{"key":"10.1016\/j.ijpx.2025.100417_bb0330","first-page":"401","article-title":"Functionalized liposomes for targeted breast cancer drug delivery","volume":"24","author":"Nel","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.ijpx.2025.100417_bb0335","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ijpx.2025.100417_bb0340","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1080\/10428194.2020.1845333","article-title":"Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies","volume":"62","author":"Pacoureau","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ijpx.2025.100417_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1513913","article-title":"Epidemiology, clinical characteristics and potential mechanism of ibrutinib-induced ventricular arrhythmias","volume":"15","author":"Pan","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0350","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s13346-024-01555-4","article-title":"Dynamic intervention to enhance the stability of PEGylated Ibrutinib loaded lipidic nano-vesicular systems: transitioning from colloidal dispersion to lyophilized product","volume":"14","author":"Panchal","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijpx.2025.100417_bb0355","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1208\/s12249-023-02586-9","article-title":"Core shell lipid-polymer hybrid nanoparticles for oral bioavailability enhancement of ibrutinib via lymphatic uptake","volume":"24","author":"Patel","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2025.100417_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123056","article-title":"Ibrutinib amorphous solid dispersions with enhanced dissolution at colonic pH for the localized treatment of colorectal cancer","volume":"641","author":"Patel","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100417_bb0365","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12668-025-01853-2","article-title":"Hyaluronic acid conjugated liposomes for targeted delivery of ibrutinib: in vitro, cell line, and in vivo assessment","volume":"15","author":"Patel","year":"2025","journal-title":"BioNanoSci"},{"key":"10.1016\/j.ijpx.2025.100417_bb0370","first-page":"100","article-title":"Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia","volume":"61","author":"Patton","year":"2024","journal-title":"Semin. Hematol. Chron. Lymphocytic Leukemia"},{"key":"10.1016\/j.ijpx.2025.100417_bb0375","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0380","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2174\/0929867327666200130101605","article-title":"Nanoparticles in combating cancer: opportunities and limitations: a brief review","volume":"28","author":"Pedziwiatr-Werbicka","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ijpx.2025.100417_bb0385","series-title":"Collagen Nanobubbles as Efficient Carriers for Targeted Controlled Release of Ibrutinib","author":"Pi\u015fkin","year":"2024"},{"key":"10.1016\/j.ijpx.2025.100417_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2024.124731","article-title":"In-vivo pharmacokinetic study of ibrutinib-loaded nanostructured lipid carriers in rat plasma by sensitive spectrofluorimetric method using harmonized approach of quality by design and white analytical chemistry","volume":"321","author":"Prajapati","year":"2024","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.ijpx.2025.100417_bb0395","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/10837450.2024.2436190","article-title":"Formulation and evaluation of ibrutinib-loaded glycyrrhizic acid conjugated ovalbumin nanoparticles and ibrutinib-glycyrrhizic acid complex for improved oral bioavailability","volume":"29","author":"Prakash Kamath","year":"2024","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0400","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1208\/s12249-018-1147-4","article-title":"Novel self-assembled ibrutinib-phospholipid complex for potently peroral delivery of poorly soluble drugs with pH-dependent solubility","volume":"19","author":"Qiu","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2025.100417_bb0405","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.actbio.2019.05.030","article-title":"Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy","volume":"92","author":"Qiu","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ijpx.2025.100417_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123787","article-title":"Targeted delivery and apoptosis induction of CDK-4\/6 inhibitor loaded folic acid decorated lipid-polymer hybrid nanoparticles in breast cancer cells","volume":"651","author":"Rajana","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100417_bb0415","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/pharmaceutics14020279","article-title":"Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma","volume":"14","author":"Ramalho","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2025.100417_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114009","article-title":"Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib","volume":"229","author":"Ran","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijpx.2025.100417_bb0425","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1208\/s12249-019-1524-7","article-title":"Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability","volume":"20","author":"Rangaraj","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2025.100417_bb0430","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1007\/s13346-020-00803-7","article-title":"QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach","volume":"10","author":"Rangaraj","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijpx.2025.100417_bb0435","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3324\/haematol.2022.282466","article-title":"Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia","volume":"109","author":"Rey-Barroso","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.ijpx.2025.100417_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2025.100213","article-title":"Optimizing ibrutinib bioavailability: Formulation and assessment of hydroxypropyl-\u03b2-cyclodextrin-based nanosponge delivery systems","volume":"8","author":"Sampathi","year":"2025","journal-title":"Curr. Res. Pharmacol. Drug Discovery"},{"key":"10.1016\/j.ijpx.2025.100417_bb0445","series-title":"Small Molecules in Oncology","first-page":"259","article-title":"Ibrutinib","author":"Schwarzbich","year":"2014"},{"key":"10.1016\/j.ijpx.2025.100417_bb0450","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/17435889.2025.2466409","article-title":"Emerging nanocarriers as advanced delivery tools for the treatment of leukemia","volume":"20","author":"Sen","year":"2025","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ijpx.2025.100417_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.105052","article-title":"Quality by design accredited self-nanoemulsifying delivery of ibrutinib for extenuating the fast-fed variability, ameliorating the anticancer activity and oral bioavailability in prostate cancer","volume":"89","author":"Shah","year":"2023","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122474","article-title":"Anticancer potential of curcumin-cyclodextrin complexes and their pharmacokinetic properties","volume":"631","author":"Shahriari","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100417_bb0465","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3390\/cancers14122868","article-title":"An updated review on EPR-based solid tumor targeting nanocarriers for cancer treatment","volume":"14","author":"Sharifi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ijpx.2025.100417_bb0470","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12247-019-09402-7","article-title":"Improving the solubility and dissolution of ibrutinib by preparing solvates","volume":"15","author":"Shi","year":"2020","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.ijpx.2025.100417_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2020.112649","article-title":"PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: in vitro and in vivo assessment","volume":"303","author":"Singh","year":"2020","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ijpx.2025.100417_bb0480","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1208\/s12249-024-02912-9","article-title":"Thermally-induced supersaturation approach for optimizing drug loading and biopharmaceutical properties of supersaturated lipid-based formulations: case studies with ibrutinib and enzalutamide","volume":"25","author":"Sirvi","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2025.100417_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125079","article-title":"Influence of polymer and surfactant-based precipitation inhibitors on supersaturation-driven absorption of Ibrutinib from high-dose lipid-based formulations","volume":"669","author":"Sirvi","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100417_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103912","article-title":"Preparation and evaluation of ibrutinib lipid-based formulations","volume":"77","author":"Song","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0495","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.113","article-title":"Realizing precision medicine in chronic lymphocytic leukemia: remaining challenges and potential opportunities","volume":"8","author":"Stamatopoulos","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.ijpx.2025.100417_bb0500","doi-asserted-by":"crossref","DOI":"10.1002\/jbm.b.35320","article-title":"pH-responsive resveratrol-loaded ZIF-8 nanoparticles modified with tannic acid for promoting colon cancer cell apoptosis","volume":"112","author":"Sun","year":"2024","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"10.1016\/j.ijpx.2025.100417_bb0505","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jare.2024.08.023","article-title":"Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance","volume":"73","author":"Sun","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ijpx.2025.100417_bb0510","series-title":"Solubility Enhancement of Ibrutinib Using Complexation with Substituted Cyclodextrins: Preparation and Characterization of Ibrutinib-Cyclodextrin Complexes (Ph.D.)","author":"Swarna","year":"2024"},{"key":"10.1016\/j.ijpx.2025.100417_bb0515","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10973-024-13922-x","article-title":"Effect of substituted cyclodextrins on ibrutinib solubility and characterization of IBR-cyclodextrin inclusion complexes by isothermal titration calorimetry in solution state","volume":"150","author":"Swarna","year":"2025","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.ijpx.2025.100417_bb0520","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3390\/cells11081338","article-title":"Ibrutinib in the treatment of solid tumors: current state of knowledge and future directions","volume":"11","author":"Szklener","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ijpx.2025.100417_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108242","article-title":"Small-molecule BTK inhibitors: from discovery to clinical application","volume":"157","author":"Tian","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ijpx.2025.100417_bb0530","series-title":"PEGylated Nanocarriers in Medicine and Pharmacy","first-page":"171","article-title":"PEGylation as a tool to alter immunological properties of nanocarriers","author":"Tiwari","year":"2025"},{"key":"10.1016\/j.ijpx.2025.100417_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.jksus.2022.102182","article-title":"An overview on therapeutic efficacy and challenges of nanoparticles in blood cancer therapy","volume":"34","author":"Wang","year":"2022","journal-title":"J. King Saud Univ. - Sci."},{"key":"10.1016\/j.ijpx.2025.100417_bb0540","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s42114-024-01053-8","article-title":"A comprehensive review of conventional and stimuli-responsive delivery systems for bioactive peptides: from food to biomedical applications","volume":"8","author":"Wang","year":"2024","journal-title":"Adv. Compos. Hybrid Mater."},{"key":"10.1016\/j.ijpx.2025.100417_bb0545","article-title":"A dual-function CD47-targeting nano-drug delivery system used to regulate immune and anti-inflammatory activities in the treatment of atherosclerosis","volume":"13","author":"Wang","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ijpx.2025.100417_bb0550","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.2023021959","article-title":"Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL","volume":"143","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ijpx.2025.100417_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122436","article-title":"Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma","volume":"630","author":"Yang","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100417_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121476","article-title":"Preparation of carbon nanotubes and polyhedral oligomeric-reinforced molecularly imprinted polymer composites for drug delivery of gallic acid","volume":"615","author":"Zhang","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100417_bb0565","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.2147\/IJN.S454004","article-title":"Advancements in stimulus-responsive co-delivery nanocarriers for enhanced cancer immunotherapy","volume":"19","author":"Zhang","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2025.100417_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139196","article-title":"A stimuli-responsive drug delivery system based on konjac glucomannan, carboxymethyl chitosan and mesoporous polydopamine nanoparticles","volume":"292","author":"Zhao","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijpx.2025.100417_bb0575","first-page":"C1231","article-title":"Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology","volume":"323","author":"Zheng","year":"2022","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.ijpx.2025.100417_bb0580","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/ph16010098","article-title":"Cardiovascular toxicities of ibrutinib: a pharmacovigilance study based on the United States food and drug administration adverse event reporting system database","volume":"16","author":"Zheng","year":"2023","journal-title":"Pharmaceuticals"}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156725001021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156725001021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:46:56Z","timestamp":1765932416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156725001021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":116,"alternative-id":["S2590156725001021"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2025.100417","relation":{},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of advanced nanocarrier systems for Ibrutinib delivery: overcoming pharmacokinetic barriers and enabling targeted cancer therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2025.100417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100417"}}